Concord Biotech Board of Directors
Get the latest insights into the leadership at Concord Biotech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Sudhir Vaid | Chairman & Managing Director |
| Ankur Vaid | Joint Managing Director & CEO |
| Ravi Kapoor | Non Executive Director |
| Rajiv Ambrish Agarwal | Non Executive Director |
| Bharti Khanna | Non Executive Independent Director |
| Amitabh Thakore | Non Executive Independent Director |
| Arvind Agarwal | Non Executive Independent Director |
| Jayaram Easwaran | Non Executive Independent Director |
| Mandayam Chakravarthy Sriraman | Non Executive Independent Director |
| Paritosh Trivedi | Company Secretary, Compliance Officer and Nodal Officer |
Concord Biotech FAQs
The board at Concord Biotech consists of experienced professionals, including Sudhir Vaid, Ankur Vaid, and others, overseeing the company’s strategic and corporate governance.
Directors at Concord Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Sudhir Vaid is the current chairman at Concord Biotech.
Executive directors at Concord Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Concord Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Concord Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
